Candriam SCA’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Candriam SCA’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-90,000	Closed	-$8.89M	–	897
2023 Q1	$8.89M	Buy	90,000 +15,000	+20%	+$1.73M	0.06%	271
2022 Q4	$8.25M	Sell	75,000 -15,000	-17%	-$973K	0.06%	309
2022 Q3	$5.31M	Buy	+90,000	New	+$4.12M	0.04%	365

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

Candriam SCA's RXDX Position: Q2 2023 in Review

Candriam SCA sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 90,000 shares — an estimated $8.89M sold.

Candriam SCA first reported a position in RXDX in Q3 2022 and held it in 3 quarters. The position peaked at $8.89M in Q1 2023. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

Candriam SCA reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Candriam SCA sold 90,000 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $8.89M.
Candriam SCA first reported a position in Prometheus Biosciences, Inc. Common Stock in Q3 2022 and held it in 3 quarters.
Candriam SCA's Prometheus Biosciences, Inc. Common Stock position peaked at $8.89M in Q1 2023.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on Candriam SCA's 13F filing for Q2 2023, filed 8 Aug 2023.